News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Video
22 July 2026

Wartsila: ECAs need to up emerging market risk

TXF spoke with Andreas Back, Product Security Development Manager at Wartsila to outline the major challenges and opportunities for major EPCs tapping ECA support, as well as...

Perspective
24 July 2026

GCC: When ECAs hit the country ceiling

Fragmented Gulf procurement, tighter local liquidity, strained country limits and Saudi-scale ambition are forcing ECAs beyond the classic tied facility. Shopping lines,...